Skip to content
Peptide research

Tesamorelin

Also known as Egrifta
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
FDA-approved

What it is

A stabilized GHRH analog, FDA-approved to reduce visceral fat in HIV lipodystrophy, used off-label for fat loss, lipid gains, and GH restoration. Evidence is strong for those effects, muscle gains are modest, and cognitive benefit is only weakly supported. Injections often cause site reactions and joint aches, effects reverse once stopped, and a theoretical cancer risk from IGF-1 is unresolved. FDA-approved, though longevity use is off-label.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Visceral fat reduction

    High

    FDA-approved indication, confirmed in two large phase 3 RCTs in HIV lipodystrophy.

  • Lipid improvement

    High

    Significant triglyceride and cholesterol ratio improvements in RCTs, though LDL unchanged.

  • Liver fat/NAFLD

    High

    Reduced liver fat and fibrosis progression in a 12-month RCT, limited to HIV cohorts.

Evidence limits

Evidence Level
Level 1 — FDA Approved

Two pivotal Phase III RCTs (n=806 combined) led to FDA approval 2010. Additional RCTs for NAFLD, muscle composition, cognition. 2026 meta-analysis of 5 RCTs confirmed efficacy. Long-term data to 52 weeks.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active malignancy

    Absolute

    FDA label: discontinue if active malignancy develops. GH promotes tumor growth.

  • Disruption of hypothalamic-pituitary axis from surgery/radiation

    High

    May not work if pituitary is damaged — requires functional somatotrophs.

  • Diabetic retinopathy

    High

    GH elevation can worsen proliferative retinopathy.

General cautions

  • Pregnancy

    Absolute

    FDA label: can cause fetal harm based on mechanism of action.

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Injection site reactions (most common)

    High
  • Arthralgia, pain in extremities, peripheral edema, myalgia

    Moderate
  • 50% develop anti-tesamorelin antibodies (no apparent efficacy impact)

    Low
  • Increased risk of developing diabetes: HbA1c reached at least 6.5% in 5% versus 1% on placebo.

    Moderate
  • Effects reverse upon cessation — requires ongoing treatment

    High
  • Theoretical cancer risk with long-term GH/IGF-1 elevation

    Theoretical
  • Contraindicated: pregnancy, active malignancy, disrupted hypothalamic-pituitary axis

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.